卵巢内注射富血小板血浆在辅助生殖中的应用:操之过急?
本文综述卵巢内注射富血小板血浆(PRP)用于辅助生殖的现有文献,探讨其潜在机制与安全性。仅少量病例报告显示有前景的结果,但机制与安全性知识有限,作者认为立即临床应用可能为时过早,需进一步基础与临床研究。
要点
- 卵巢内注射PRP的临床数据仅来自少量病例报告,机制与安全性尚不明确。
- PRP含血小板、细胞因子和生长因子,可能通过细胞因子诱导细胞分化。
- 作者建议暂缓临床常规应用,需进一步研究卵巢功能不全本质及PRP作用机制。
核心结论
- 基于现有知识,立即将PRP用于临床可能为时过早,需进一步基础与临床研究。
研究设计与样本
- 本文为综述,总结血小板与PRP的生理细节并回顾该领域现有新兴文献。
主要发现
- 少量病例报告描述人卵巢内注射PRP,临床数据报告有前景的结果。
- PRP含血小板、细胞因子、生长因子及小分子,已在多种再生医学方法中研究。
- PRP已被证明可诱导多种细胞类型分化,推测通过细胞因子作用。
临床怎么用
- 临床暂不宜常规开展卵巢内注射PRP,应限于研究背景下进行。
局限性
- PRP注射入卵巢的机制与安全性知识仍有限。
- 现有临床证据仅来自少量病例报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prospect of ovarian rejuvenation offers the tantalising prospect of treating age-related declines in fertility or in pathological conditions such as premature ovarian failure. The concept of ovarian rejuvenation was invigorated by the indication of the existence of oogonial stem cells (OSCs), which have been shown experimentally to have the ability to differentiate into functional follicles and generate oocytes; however, their clinical potential remains unknown. Furthermore, there is now growing interest in performing ovarian rejuvenation in situ. One proposed approach involves injecting the ovary with platelet rich plasma (PRP). PRP is a component of blood that remains after the in vitro removal of red and white blood cells. It contains blood platelets, tiny anucleate cells of the blood, which are responsible for forming athrombus to prevent bleeding. In addition, PRP contains an array of cytokines and growth factors, as well as a number of small molecules.The utility ofPRP has been investigatedin a range of regenerative medicine approaches and has been shown to induce differentiation of a range of cell types, presumably through the action of cytokines. A handful ofcasereports have described the use of PRP injections into the ovaryin the human, and while these clinical data report promising results, knowledge on the mechanisms and safety of PRP injections into the ovary remain limited.In this article, we summarise some of the physiological detail of platelets and PRP, before reviewing the existing emerging literature in this area. We then propose potential mechanisms by which PRP may be eliciting any effects before reflecting on some considerations for future studies in the area. Importantly, on the basis of our existing knowledge, we suggest that immediate use of PRP in clinical applications is perhaps premature and further fundamental and clinical research on the nature of ovarian insufficiency, as well as the mechanism by which PRP may act on the ovary, is needed to fully understand this promising development.
引用
- Atkinson L, Martin F, Sturmey RG, et al. Intraovarian injection of platelet-rich plasma in assisted reproduction: too much too soon? Hum Reprod. 2021. PMID: 33963408. doi:10.1093/humrep/deab106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。